COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu
Trial record 6 of 6 for:    azixa

Phase 1, Multiple Dose Study of MPC-6827 in Subjects With Refractory Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00394446
Recruitment Status : Completed
First Posted : November 1, 2006
Last Update Posted : February 13, 2008
Information provided by:
Myrexis Inc.

Brief Summary:
Phase 1, Multiple Dose Study of MPC-6827 in Subjects with Refractory Solid Tumors.

Condition or disease Intervention/treatment Phase
Refractory Solid Tumors Drug: MPC-6827 Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 48 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase I Open Label, Dose Escalating, Multiple Dose Study to Determine the Safety, Tolerability, Maximum Tolerated Dose, and Pharmacokinetics of MPC-6827 Administered IV Weekly X 3, Repeated Every 28 Days, in Subjects With Refractory Solid Tumors.
Study Start Date : March 2005
Actual Primary Completion Date : April 2007
Actual Study Completion Date : February 2008

Intervention Details:
  • Drug: MPC-6827
    2-hour intravenous infusion given once weekly for 3 consecutive weeks on a 28 day cycle

Primary Outcome Measures :
  1. Maximum Tolerated Dose [ Time Frame: 1 year ]
  2. Pharmacokinetics [ Time Frame: 22 months ]

Secondary Outcome Measures :
  1. Antitumor Activity [ Time Frame: 2 years ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Advanced or Metastatic Cancer
  2. Measurable / Evaluable Disease
  3. Karnofsky score greater than or equal to 70%
  4. Adequate Hematology / Organ function
  5. No Baseline peripheral or central neuropathy above grade 1

Exclusion Criteria:

  1. Hypersensitivity to Cremophor EL
  2. Pregnant or Lactating
  3. Spinal Cord Compression
  4. Pre-existing Dementia / Cognitive Disfunction
  5. Require Neupogen or Neulasta to Maintain Neutrophil Count
  6. Have Primary Brain Cancer
  7. Have history of Ischemic Heart Disease
  8. Have Diabetes

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00394446

Layout table for location information
United States, Texas
University of Texas MD Anderson Cancer Center
Houston, Texas, United States, 77030
United States, Utah
Huntsman Cancer Institute at the University of Utah
Salt Lake City, Utah, United States, 84112
Sponsors and Collaborators
Myrexis Inc.
Layout table for investigator information
Study Director: Margaret Yu, MD Myrexis Inc.
Layout table for additonal information
Responsible Party: Margaret Yu, MD / Director of Clinical Research, Myriad Pharmaceuticals, Inc. Identifier: NCT00394446    
Other Study ID Numbers: MPC6827-04-001
First Posted: November 1, 2006    Key Record Dates
Last Update Posted: February 13, 2008
Last Verified: February 2008
Keywords provided by Myrexis Inc.:
Solid Tumors
Additional relevant MeSH terms:
Layout table for MeSH terms